Identification of Urinary Exosomal miRNAs for the Non-Invasive Diagnosis of Prostate Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–1913. doi:10.1001/jama.2018.371029801017
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268–278. doi:10.1038/nrc235118337732
   PubMed Web of Science ®Google Scholar
• Neylon A, McGorrian C, Blake GJ. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. Int J Cardiol. 2016;224:310–316. doi:10.1016/j.ijcard.2016.09.01627665403
   PubMed Web of Science ®Google Scholar
• Giallombardo M, Chacártegui Borrás J, Castiglia M, et al. Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients’ plasma through qPCR: a feasible liquid biopsy tool. JoVE. 2016;(111). doi:10.3791/53900
   Google Scholar
• Delić D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLoS One. 2016;11(3):e0150154. doi:10.1371/journal.pone.015015426930277
   PubMed Web of Science ®Google Scholar
• Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971–26981. doi:10.18632/oncotarget.469926284486
   PubMedGoogle Scholar
• Cappello F, Logozzi M, Campanella C, et al. Exosome levels in human body fluids: a tumor marker by themselves? Eur J Pharm Sci. 2017;96:93–98. doi:10.1016/j.ejps.2016.09.01027640113
   PubMed Web of Science ®Google Scholar
• Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13(1):17–24. doi:10.1016/j.gpb.2015.02.00125724326
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289. doi:10.1146/annurev-cellbio-101512-12232625288114
   PubMed Web of Science ®Google Scholar
• Franzen CA, Blackwell RH, Foreman KE, Kuo PC, Flanigan RC, Gupta GN. Urinary exosomes: the potential for biomarker utility, intercellular signaling and therapeutics in urological malignancy. J Urol. 2016;195(5):1331–1339. doi:10.1016/j.juro.2015.08.11526714199
   PubMed Web of Science ®Google Scholar
• Iwai K, Minamisawa T, Suga K, Yajima Y, Shiba K. Isolation of human salivary extracellular vesicles by iodixanol density gradient ultracentrifugation and their characterizations. J Extracell Vesicles. 2016;5:30829. doi:10.3402/jev.v5.3082927193612
   PubMed Web of Science ®Google Scholar
• Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476. doi:10.1038/ncb180019011622
   PubMed Web of Science ®Google Scholar
• Cheng L, Sun X, Scicluna BJ, Coleman BM, Hill AF. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014;86(2):433–444. doi:10.1038/ki.2013.50224352158
   PubMed Web of Science ®Google Scholar
• Gildea JJ, Carlson JM, Schoeffel CD, Carey RM, Felder RA. Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure. Clin Biochem. 2013;46(12):1131–1134. doi:10.1016/j.clinbiochem.2013.05.05223726803
   PubMed Web of Science ®Google Scholar
• Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33–41. doi:10.1016/j.eururo.2014.07.03525129854
   PubMed Web of Science ®Google Scholar
• Haflidadóttir BS, Ceder Y. Exosomal microRNAs as potential biomarkers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):42–43. doi:10.1016/j.eururo.2014.08.06725199715
   PubMed Web of Science ®Google Scholar
• Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921. doi:10.1371/journal.pone.009292124705249
   PubMed Web of Science ®Google Scholar
• Corcoran C, Rani S, O’Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014;74(13):1320–1334. doi:10.1002/pros.2284825053345
   PubMed Web of Science ®Google Scholar
• Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet. 2013;4:36. doi:10.3389/fgene.2013.0003623519132
   PubMedGoogle Scholar
• Li Z, Ma YY, Wang J, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther. 2016;9:139–148. doi:10.2147/OTT.S9556526770063
   PubMed Web of Science ®Google Scholar
• Selth LA, Townley S, Gillis JL, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012;131(3):652–661. doi:10.1002/ijc.2640522052531
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–10518. doi:10.1073/pnas.080454910518663219
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif). 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Situ J, Zhang H, Jin Z, Li K, Mao Y, Huang W. MicroRNA-939 directly targets HDGF to inhibit the aggressiveness of prostate cancer via deactivation of the WNT/β-catenin pathway. Onco Targets Ther. 2020;13:4257–4270. doi:10.2147/OTT.S25010132547060
   PubMed Web of Science ®Google Scholar
• Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, Mearini E. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 2016;9:7545–7553. doi:10.2147/OTT.S11902728008272
   PubMed Web of Science ®Google Scholar
• Guelfi G, Cochetti G, Stefanetti V, et al. Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research. Sci Rep. 2018;8(1):7111. doi:10.1038/s41598-018-24236-y29740090
   PubMed Web of Science ®Google Scholar
• Mearini E, Antognelli C, Del Buono C, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers. 2009;14(4):235–243. doi:10.1080/1354750090280730619489685
   PubMed Web of Science ®Google Scholar
• Talesa VN, Antognelli C, Del Buono C, et al. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomarkers. 2009;5(6):241–251. doi:10.3233/CBM-2009-010920037200
   PubMed Web of Science ®Google Scholar
• Errico G, Gagliotti C, Monaco M, et al. Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy. Clin Microbiol Infect. 2019;25(2):203–209. doi:10.1016/j.cmi.2018.05.00329800674
   PubMed Web of Science ®Google Scholar
• Gagliotti C, Morsillo F, Moro ML, et al. Infections in liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis. 2018;37(3):399–407. doi:10.1007/s10096-018-3183-029380226
   PubMed Web of Science ®Google Scholar
• Egidi MG, Cochetti G, Guelfi G, et al. Stability assessment of candidate reference genes in urine sediment of prostate cancer patients for miRNA applications. Dis Markers. 2015;2015:973597. doi:10.1155/2015/97359726078486
   PubMed Web of Science ®Google Scholar
• Rende M, Rambotti MG, Stabile AM, et al. Novel localization of low affinity NGF receptor (p75) in the stroma of prostate cancer and possible implication in neoplastic invasion: an immunohistochemical and ultracytochemical study. Prostate. 2010;70(5):555–561. doi:10.1002/pros.2108919918800
   PubMed Web of Science ®Google Scholar
• Baldassarri M, Fallerini C, Cetta F, et al. Omic approach in non-smoker female with lung squamous cell carcinoma pinpoints to germline susceptibility and personalized medicine. Cancer Research Treat. 2018;50(2):356–365. doi:10.4143/crt.2017.125
   PubMed Web of Science ®Google Scholar
• Cochetti G, Rossi de Vermandois JA, Maulà V, et al. Role of miRNAs in prostate cancer: do we really know everything? Urol Oncol. 2020;38(7):623–635. doi:10.1016/j.urolonc.2020.03.00732284256
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469. doi:10.1016/j.molmed.2014.06.00525027972
   PubMed Web of Science ®Google Scholar
• Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60. doi:10.1186/1476-4598-6-6017894887
   PubMed Web of Science ®Google Scholar
• Zhang W, Peng P, Shen K. Role of exosome shuttle RNA in cell-to-cell communication. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016;38(4):480–483. doi:10.3881/j.issn.1000-503X.2016.04.02027594165
   PubMedGoogle Scholar
• Foj L, Ferrer F, Serra M, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 2017;77(6):573–583. doi:10.1002/pros.2329527990656
   PubMed Web of Science ®Google Scholar
• Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17(11):1784. doi:10.3390/ijms17111784
   PubMed Web of Science ®Google Scholar
• Fukumoto I, Kinoshita T, Hanazawa T, et al. Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. Br J Cancer. 2014;111(2):386–394. doi:10.1038/bjc.2014.29324918822
   PubMed Web of Science ®Google Scholar
• Li M, Song Q, Li H, Lou Y, Wang L. Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma. PLoS One. 2015;10(7):e0132403. doi:10.1371/journal.pone.013240326168287
   PubMed Web of Science ®Google Scholar
• Babapoor S, Fleming E, Wu R, Dadras SS. A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion. PLoS One. 2014;9(9):e107502. doi:10.1371/journal.pone.010750225237911
   PubMed Web of Science ®Google Scholar
• Riquelme I, Tapia O, Leal P, et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordrecht). 2016;39(1):23–33. doi:10.1007/s13402-015-0247-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Ji C, Guo S, et al. The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget. 2017;8(42):72835–72846. doi:10.18632/oncotarget.2042729069829
   PubMedGoogle Scholar
• Pickl JM, Tichy D, Kuryshev VY, et al. Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget. 2016;7(37):59589–59603. doi:10.18632/oncotarget.1072927449098
   PubMedGoogle Scholar
• Wach S, Al-Janabi O, Weigelt K, et al. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer. 2015;137(6):1406–1416. doi:10.1002/ijc.2950525754273
   PubMed Web of Science ®Google Scholar
• Choi N, Park J, Lee JS, et al. miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. Oncotarget. 2015;6(27):23533–23547. doi:10.18632/oncotarget.437226124181
   PubMedGoogle Scholar
• Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608–616. doi:10.1002/ijc.2537620473869
   PubMed Web of Science ®Google Scholar